Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
29.10. | Mindbio Therapeutics Corp: Mindbio sees 72% drop in depression 6M after treatment | 12 | Stockwatch | ||
MINDBIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
29.10. | MindBio Therapeutics: MindBio Reports a 72% Reduction in Severity of Depression Sustained Six Months After Treatment in Clinical Trials | 2 | TheNewswire | ||
24.10. | Mindbio Therapeutics Corp: Mindbio begins dosing 20th patient in MB22001 trial | 3 | Stockwatch | ||
24.10. | MindBio Therapeutics: Mindbio Announces Clinical Trial Milestone In Phase 2B Microdosing Trials Targeting Existential Distress, Depression & Anxiety In Advanced Stage Cancer | 3 | TheNewswire | ||
22.10. | Mindbio Therapeutics Corp: Mindbio completes trial post-treatment milestone | 10 | Stockwatch | ||
22.10. | MindBio Therapeutics: MindBio Completes Final Post Treatment Milestone in Phase 2A Microdosing Depression Clinical Trial. Results to be Reported in the Coming Fortnight | 2 | TheNewswire | ||
16.10. | Mindbio Therapeutics Corp: Mindbio arranges $200,000 private placement | 3 | Stockwatch | ||
16.10. | MindBio Therapeutics: MindBio Announces Proposed Issuance of Listed Securities | 3 | TheNewswire | ||
08.10. | Mindbio Therapeutics Corp: Mindbio hits 12 months of shelf stability for MB22001 | 10 | Stockwatch | ||
08.10. | MindBio Therapeutics: MindBio Develops Long Term Shelf-Stable Microdosing Formulation and is Progressing in Multiple Phase 2B Clinical Trials | 3 | TheNewswire | ||
23.09. | Mindbio Therapeutics Corp: Mindbio enrols 25th participant in MB22001 trial | 2 | Stockwatch | ||
23.09. | MindBio Therapeutics Enrols 25th Participant into Landmark Take-Home Microdosing Depression Trial | 4 | TheNewswire | ||
29.08. | MindBio advances world-first psychedelic microdosing clinical trials | 3 | The Market Herald Canada | ||
29.08. | MindBio Therapeutics: MindBio CEO Provides Video Update to Shareholders on Progress of World First, Government Approved Microdosing Clinical Trials | 1 | TheNewswire | ||
19.08. | Mindbio Therapeutics Corp: Mindbio Therapeutics reviews MB22001 testing data | 3 | Stockwatch | ||
19.08. | MindBio Therapeutics: MindBio Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials | 374 | ACCESSWIRE | Three months post cessation of an 8-week course of microdosing treatment, the antidepressant response is sustained with a 62.8% reduction in depressive symptoms. VANCOUVER, BC / ACCESSWIRE / August... ► Artikel lesen | |
01.08. | Mindbio Therapeutics Corp: Mindbio appoints Haywood Securities as adviser | 5 | Stockwatch | ||
01.08. | MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory | 371 | ACCESSWIRE | VANCOUVER, BC / ACCESSWIRE / August 1, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a leading biopharmaceutical company in psychiatric medicine development... ► Artikel lesen | |
08.07. | Mindbio Therapeutics Corp: Mindbio to start dosing in MB22001 phase 2B trial | 11 | Stockwatch | ||
20.06. | Mindbio Therapeutics Corp: Mindbio says MB22001 shows antidepressant response | 10 | Stockwatch |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BAYER | 19,802 | +1,46 % | Crash-Alarm: Bayer auf Rekordtief: Was kommt nach dem Milliarden-Debakel? | © Foto: picture alliance/dpa | Oliver BergDie Bayer-Aktie fällt auf ein 20-Jahres-Tief, Analysten senken Kursziele, und der Wettbewerb verschärft sich durch neue Biosimilare im Pharmabereich.Die Bayer... ► Artikel lesen | |
PFIZER | 24,610 | -0,02 % | Kaufen oder Verkaufen?: Die spannende Zukunft von BioNTech, Pfizer & Co. | © Foto: SymbolbildAktien von BioNTech, Moderna und Pfizer geraten gerade ordentlich unter Druck - und das aus gutem Grund. Ex-Präsident Donald Trump hat einen überraschenden Schachzug gemacht, der die... ► Artikel lesen | |
GILEAD SCIENCES | 86,67 | +0,10 % | Gilead's Livdelzi Shows Sustained Efficacy, Long-Term Safety In PBC Management | FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% of participants with... ► Artikel lesen | |
AURORA CANNABIS | 4,186 | +0,58 % | Aurora Cannabis Inc (3): Aurora Cannabis releases new recreational products | ||
SANOFI | 92,40 | -0,18 % | Aktie von Sanofi SA: Kurs mit wenig Bewegung (90,48 €) | Der Kurs der der Sanofi SA-Aktie kommt kaum von der Stelle. Der jüngste Kurs betrug 90,48 Euro. Wenig getan hat sich heute bislang beim Kurs von Sanofi SA. Mit einem Preis von 90,48 Euro notiert das... ► Artikel lesen | |
GSK | 16,295 | +2,65 % | GSK Plc Announces Regulatory Expansion For Arexvy In Japan To Include Adults Aged 50-59 | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - GSK plc (GSK, GSK.L) announced that Japan's Ministry of Health, Labour and Welfare has approved a regulatory application to extend the indication of Arexvy... ► Artikel lesen | |
CANOPY GROWTH | 3,730 | -0,53 % | What's Happening With Canopy Growth: Is It Time To Buy? | ||
TILRAY BRANDS | 1,290 | -0,27 % | Tilray Brands Inc: Tilray, Montlake team release game-day gold lager | ||
INNOCAN PHARMA | 0,148 | -1,67 % | Innocan Pharma meldet Finanzergebnisse für das dritte Quartal 2024 | 2,7-facher Umsatzzuwachs im Jahresvergleich auf 24 Mio. US$ im Zeitraum von 9 Monaten
Herzliya, Israel und Calgary, Alberta - 20. November 2024 / IRW-Press / Innocan Pharma Corporation... ► Artikel lesen | |
TAAT GLOBAL ALTERNATIVES | 0,115 | +4,07 % | XFRA 2TP0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
DERMAPHARM | 37,500 | 0,00 % | Dermapharm Aktie: Vorfreude ist spürbar! | ||
SYNBIOTIC | 5,580 | +2,20 % | EQS-Adhoc: SYNBIOTIC SE: SynBiotic SE schließt Einbringungsvertrag über den Erwerb von 50,2 % der Anteile an der greensby UG (haftungsbeschränkt), Vettweiss, ab. | EQS-Ad-hoc: SYNBIOTIC SE / Schlagwort(e): Beteiligung/Unternehmensbeteiligung
SynBiotic SE schließt Einbringungsvertrag über den Erwerb von 50,2 % der Anteile an der greensby UG (haftungsbeschränkt)... ► Artikel lesen | |
TRANSCANNA | 0,017 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 02.07.2024 | The following instruments on XETRA do have their last trading day on 02.07.2024Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 02.07.2024ISIN NameGB00BMGRFP88 CITIUS RESOURCES LS-... ► Artikel lesen | |
EYEPOINT PHARMACEUTICALS | 8,616 | +0,42 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
BAUSCH HEALTH | 7,869 | +2,90 % | Bausch Health Companies Inc.: Bausch Health and Salix to Present at the American Association for the Study of Liver Disease the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis | Next generation product may increase gastrointestinal luminal concentration while limiting system exposure LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC)... ► Artikel lesen |